Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used in the treatment of non–small cell lung cancer (NSCLC) with EGFR mutations.1 This evidence concerns the gene EGFR and non-small cell lung carcinoma.